• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2006 Fiscal Year Final Research Report Summary

Development of Molecular target drug for ADPKD

Research Project

Project/Area Number 17591702
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Urology
Research InstitutionTeikyo University

Principal Investigator

HORIE Shigeo  Teikyo University, School of Medicine, Department Urology, Chairman & professor, 医学部, 教授 (40190243)

Co-Investigator(Kenkyū-buntansha) MUTO Satoru  Teikyo University, School of Medicine, Department Urology, Associate professor, 医学部, 講師 (30345194)
Project Period (FY) 2005 – 2006
KeywordsADPKD / Angiotensin receptor blocker / ω3 unsaturated fatty acid
Research Abstract

Purpose: It is well known that the administration of soy-bean dramatically reduces both tubular and interstitial pathology in the Han : SPRD-cy rat model of PKD, through mechanisms that is known to enhance the conversion of polyunsaturated fatty acids to docosahexaenoic acid. We evaluated the efficacy of Ethyl icosapentate (Epadel【○!R】:EPA) and Angiotensin receptor blocker (ARB : telmisartan or candesartan) for ADPKD patients.
Patients and Methods: Forty-two ADPKD patients without dialysis therapy were included in this study. We randomly assigned 42 participants to no treatment, ARB monotherapy, and EPA+ARB combined therapy regimens. We compared the blood pressure, renal function and renal size between each groups.
Results: Twenty-four patients (mean age 52.8±13.9 years) were allocated to the no-treatment group, 9 patients (50.0±11.5 years) were allocated to the ARB monotherapy group, and 9 patients (48.1±9.1 years) were allocated to the EPA+ARB group. Although in the no-treatment group, Ccr was significantly decreased from 69.8±22.9m1/min to 47.9±21.0ml/min for 12 months periods (p=0.038), in the ARB monotherapy group (pre: 73.6±51.6ml/min, 12 Mo later: 58.4±37.0ml/min, p=0.589) and the EPA+ARB group (pre: 50.2±17.2ml/min, 12 Mo later: 40.6±23.6ml/min, p=0.468), Ccr was decreased for 12 months, but not significantly. Renal volume was lower in the EPA+ARB group (2756.4±1065.6ml) than in the no-treatment group (1911.8±1109.9ml) at 12 months, but not significantly.
Conclusions: This study suggested that the renoprotective effect of EPA+ARB may be considered more favorable than ARB monotherapy in the treatment of ADPKD.

  • Research Products

    (6 results)

All 2007 2005

All Journal Article (6 results)

  • [Journal Article] PKD1 Haploinsufficiency Causes a Syndrome of Inappropriate Antidiuresis in Mice.2007

    • Author(s)
      Ahrabi AK
    • Journal Title

      J Am Soc Nephrol 18(6)

      Pages: 1740-1753

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] ADPKD : molecular characterization and quest for treatment.2005

    • Author(s)
      Horie S
    • Journal Title

      Clin Exp Nephrol 9(4)

      Pages: 282-291

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Molecular targeting drug designing for polycystic kidney.2005

    • Author(s)
      Horie S
    • Journal Title

      Nippon Naika Gakkai Zasshi 94(6)

      Pages: 1165-1171

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation.2005

    • Author(s)
      Nishio S
    • Journal Title

      J Clin Invest 115(4)

      Pages: 910-918

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.2005

    • Author(s)
      Nutahara K
    • Journal Title

      Nephron Clin Pract 99(1)

      Pages: c18-23

    • Description
      「研究成果報告書概要(和文)」より
  • [Journal Article] molecular characterization and quest for treatment2005

    • Author(s)
      Horie S, ADPKD
    • Journal Title

      Clin Exp Nephrol 9(4)

      Pages: 282-91

    • Description
      「研究成果報告書概要(欧文)」より

URL: 

Published: 2008-05-27  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi